Integrating AI-driven engagement with licensed pharmacy infrastructure to streamline prescription fulfillment and improve medication adherence
WASHINGTON–(BUSINESS WIRE)–#CaryHealth—CaryHealth, a leading digital health company, today formally announced the launch of its direct-to-patient (DTP) platform, designed to streamline the patient journey: from clinical and telehealth consultations through delivery and adherence support.
CaryHealth’s platform connects clinical support, pharmacy fulfillment, and real-time data tracking throughout the patient journey. By combining AI-driven engagement with the supply chain strength of its nationally licensed pharmacy, CaryHealth delivers a seamless, end-to-end experience. This integration makes access simpler for patients while giving manufacturers confidence that therapies reach patients consistently, safely, and at scale.
By personalizing engagement at every touchpoint via CaryHealth’s clinical sequencing engine, patients are supported, connected, and more likely to adhere to treatment.
In real-time, manufacturers gain actionable insights through the CaryConnect dashboard which incorporates dynamic reporting and A/B testing for patient outreach optimization and overall program performance. By leveraging our enterprise-grade data fabric and agentic automation layer, this approach empowers pharmaceutical manufacturers to minimize time-to-first-fill and enhance adherence through continuous experience optimization—capabilities that traditional pharmacies are not architected to support.
“While the shift toward the direct-to-patient model is inevitable, its success hinges on reimagining the patient journey, not just traditional distribution,” said Areo Nazari, CEO and co-founder of CaryHealth. “CaryHealth delivers a customizable and unified digital experience where every touchpoint is connected, personalized, and powered by modern UI/UX frameworks. Too many DTP experiences today are fragmented as a result of using multiple digital engagement vendors. By integrating digital experience, clinical engagement, scalable supply chain orchestration and actionable data, our platform builds patient trust, drives adherence and helps therapies achieve their full potential.”
CaryHealth’s direct-to-patient capabilities are trusted by global partners across a wide range of therapeutic areas. The platform has been deployed by Rejoyn for major depressive disorder with Otsuka Precision Health; SleepioRx for insomnia with Big Health; Parky for Parkinson’s disease with H2O Therapeutics; Mahana IBS for irritable bowel syndrome with Mahana Therapeutics, and more.
To learn more about CaryHealth’s DTP offering, please visit:
About CaryHealth
CaryHealth is an AI-enabled digital pharmacy and healthcare technology company redefining how patients start and stay on therapy. Our platform unites pharmacy services, intelligent automation, and data-driven engagement to simplify access, improve continuity of care, and empower patients throughout their treatment journey. By bridging the gap between life sciences, providers, and patients, CaryHealth advances equitable access and helps therapies reach their full potential.
For more information, visit https://www.cary.health.
Contacts
Media Contact:
Kate Nesbitt
Alloy Communications
kate@helloalloy.com
